During the follow-up, tumor markers increased in 12 of 21 patients (57.2%), and in patients with metachronous PC as the single site of metastasis, increased CEA was observed in 4 of 6 (67%). This evidence concerns the gene CEACAM5 and pachyonychia congenita.